Recently, the utilization of SIR as a treatment for L. major cutaneous leishmaniasis in mice led to a significant reduction of parasite burden in draining lymph nodes [30], also confirming that the use of mTOR inhibitors could be a new strategy to limit the growth of different Leishmania species. This evidence concerns the gene MTOR and cutaneous leishmaniasis.